Pacritinib is under clinical development by CTI BioPharma and currently in Phase II for Sezary Syndrome. According to GlobalData, Phase II drugs for Sezary Syndrome have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pacritinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pacritinib overview

PacritInib (Vonjo) is an anti neoplastic agent. It is formulated as hard capsules for oral route of administration, Vonjo is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50×109/L.

Pacritinib (BAX 2201, SB-1518, ONX-0803) is under development for the treatment of peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma/follicular helper T-cell (AITL/TFH) cutaneous T-cell lymphoma mycosis fungoides (MF) and Sezary syndrome (SS), myelofibrosis, post-polycythemia vera myelofibrosis, post-essential thrombocythemia myelofibrosis and graft versus host disease (GVHD). It is administered orally. It targets JAK2-selective kinase, FMS-like tyrosine kinase 3,colony stimulating factor 1 receptor (CSF1R) and interleukin-1 receptor-associated kinase 1 (IRAK1).

It was also under the development for the treatment of myelodysplastic syndrome, colorectal cancer, acute myelocytic leukemia (AML), chronic myelomonocytic leukemia (CMML), chronic lymphocytic leukemia (CLL) and lymphomas (mantle cell lymphoma, Hodgkin lymphoma, indolent lymphoma), coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

CTI BioPharma overview

CTI BioPharma, a subsidiary of Swedish Orphan Biovitrum AB, is a biopharmaceutical company that acquires, develops and commercializes novel therapies for a range of blood-related cancers. Its lead product, Pacritinib is intended for the treatment of patients with myeloproliferative diseases. Its product pipeline includes PACIFICA for the treatment of myelofibrosis patients with severe thrombocytopenia; PAC203 for the patients with ruxolitinib therapy failure; PRE-VENT for COVID-19; PERSIST 1 for all platelets count and PERSIST 2 for platelets counts less than thousand. The company’s commercialized product, Vonjo is targeted for the treatment of adult patients with myelofibrosis patients with severe thrombocytopenia. The company relies on third parties for manufacturing and marketing its products. CTI BioPharma is headquartered in Seattle, Washington, the US.

For a complete picture of Pacritinib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.